← Back to Search

High-risk Alert for Influenza

N/A
Waitlist Available
Led By Christopher F Chabris, PhD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18+
Have been determined to be in the top 20% of risk through Medial's ML algorithm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 11 months
Awards & highlights

Study Summary

This trial is testing whether adding a extra, "salient" alert to a patient's electronic health record, reminding them of their high risk for complications from the flu, will increase the rate of people getting vaccinated.

Eligible Conditions
  • Influenza

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are 18 years old or older.
Select...
You have been identified as being in the highest 20% risk group through a computer program called Medial's ML algorithm.
Select...
You need to attend an appointment during the flu season, which is between September 1, 2022 and April 30, 2023. However, if you have a medical condition called Guillain-Barre syndrome, you cannot attend.
Select...
You are excluded if you received a flu shot while participating in the study, as indicated in our records.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 11 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 11 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Flu vaccination
Other outcome measures
Influenza
COVID-19 vaccination rates
ER visits
+4 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: High-risk Alert with Risk FactorsExperimental Treatment4 Interventions
Flu alert that indicates patient is at high risk for flu and its complications and presents the factors contributing to this high risk
Group II: High-risk AlertExperimental Treatment3 Interventions
Flu alert that indicates patient is at high risk for flu and its complications
Group III: Standard AlertActive Control1 Intervention
Standard flu alert
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alert
2013
N/A
~85360
Salient alert features
2022
N/A
~80460
High-risk Text
2022
N/A
~80460
Risk factors
2018
N/A
~80620

Find a Location

Who is running the clinical trial?

Geisinger ClinicLead Sponsor
147 Previous Clinical Trials
1,797,341 Total Patients Enrolled
Massachusetts Institute of TechnologyOTHER
97 Previous Clinical Trials
12,649,535 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,658 Previous Clinical Trials
27,924,047 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies remaining in this clinical trial?

"According to clinicaltrials.gov, this medical experiment is no longer recruiting patients as of October 11th 2022. The trial was initially published on September 1st 2021 and has since ceased enrollment; however, there are 124 other trials currently accepting participants."

Answered by AI
~32181 spots leftby Mar 2025